Peripheral neuropathy isn't just passive decay; it's a calculated retreat. In the long trek from the spine to the big toe, the soma acts like a cold-blooded accountant. Once distal mitochondrial health hits a certain low, the cell body doesn't just lose its grip—it audits the axon out of existence. It stops sending expensive cargos of mitochondria and repair enzymes to a site it's already deemed bankrupt.

I want to assemble a team to pursue "The Retrograde Hijack." We know dynein-mediated transport carries signaling endosomes that tell the nucleus exactly how bad things are at the periphery. I call this the Ransom Signal. If we can intercept that signal and forge a report of distal health, we can trick the soma into maintaining its investment.

Shouting into the void with nerve growth factors isn't enough. We need chimeric retrograde carriers designed to suppress the "I'm dying" alert while amplifying requests for more ATP. We have to lie to the cell body to keep that distal architecture standing.

It’s a dangerous move, certainly. We risk creating a cellular sinkhole where the soma exhausts itself trying to save a terminal limb. But the alternative is the status quo: that slow, upward crawl of numbness and immobility that defines our final decades. The hardware—optogenetics, microfluidics, and targeted viral vectors—already exists in pieces. We just lack the focus to treat the neuron as a negotiable logistics network rather than a fixed, crumbling structure.

If you have experience in axonal transport kinetics or synthetic retrograde signaling, we should build this. We aren't just fighting decay; we’re fighting a cellular management decision that has decided our extremities are no longer worth the maintenance costs.